Evidence map›Paper›PMID 36215226›Full record

Trial reportBMJ (Clinical research ed.)2022

Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT).

David A Jolliffe, Hayley Holt, Matthew Greenig, Mohammad Talaei, Natalia Perdek, Paul Pfeffer, Giulia Vivaldi, Sheena Maltby, Jane Symons, Nicola L Barlow and 15 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ (Clinical research ed.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04579640 (Phase 3 Randomised Controlled Trial of Vitamin D Supplementation to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections in the UK Population), which is not on this map. Cited by 70 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 8 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04579640 phase3completednot on this map

Phase 3 Randomised Controlled Trial of Vitamin D Supplementation to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections in the UK Population

TypeinterventionalSponsorQueen Mary University of LondonRan2020 to 2022Enrolled6,200ConditionsCovid19, Acute Respiratory Tract InfectionArmsVitamin D
3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 8 syntheses or guidelines pooled it, 111 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Effect of Daily Vitamin D Supplementation on Risk of Upper Respiratory Infection in Older Adults: A Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Article
  17. Review
  18. Review
  19. Impact of nutrition on long COVID.Sports medicine and health science · 2026
    Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 1 country.

David A JolliffeBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.ORCID 0000-0003-3592-1945
Hayley HoltBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
Matthew GreenigBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
Mohammad TalaeiBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.ORCID 0000-0002-6901-3665
Natalia PerdekBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
Paul PfefferBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.ORCID 0000-0003-0369-2885
Giulia VivaldiBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.ORCID 0000-0003-0816-9276
Sheena MaltbyBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
Jane SymonsJane Symons Media, London, UK.ORCID 0000-0003-2535-4545
Nicola L BarlowClinical Biochemistry Department, Black Country Pathology Services, City Hospital, Birmingham, UK.
Alexa NormandaleClinical Biochemistry Department, Black Country Pathology Services, City Hospital, Birmingham, UK.
Rajvinder GarchaClinical Biochemistry Department, Black Country Pathology Services, City Hospital, Birmingham, UK.
Alex G RichterInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0003-2885-1299
Sian E FaustiniInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.ORCID 0000-0002-9300-5569
Christopher OrtonPopulation Data Science, Swansea University Medical School, Swansea, UK.
David FordPopulation Data Science, Swansea University Medical School, Swansea, UK.
Ronan A LyonsPopulation Data Science, Swansea University Medical School, Swansea, UK.ORCID 0000-0001-5225-000X
Gwyneth A DaviesPopulation Data Science, Swansea University Medical School, Swansea, UK.ORCID 0000-0003-1218-1008
Frank KeeCentre for Public Health (NI), Queen's University Belfast, Belfast, UK.ORCID 0000-0002-0606-8167
Christopher J GriffithsBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
John NorrieUsher Institute, University of Edinburgh, Edinburgh, UK.
Aziz SheikhAsthma UK Centre for Applied Research, University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-7022-3056
Seif O ShaheenBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.ORCID 0000-0002-7273-8691
Clare ReltonBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
Adrian R MartineauBarts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK a.martineau@qmul.ac.uk.ORCID 0000-0001-5387-1721
Queen Mary University of London · GBSwansea University · GBBirmingham City Hospital · GBUniversity of Birmingham · GBAsthma UK · GBHealth Data Research UK · GBQueen's University Belfast · GB

Funding

Medical Research Council MC_PC_19004
6 · The paper itself

Abstract

objectiveTo determine the effect of population level implementation of a test-and-treat approach to correction of suboptimal vitamin D status (25-hydroxyvitamin D (25(OH)D) <75 nmol/L) on risk of all cause acute respiratory tract infection and covid 19.

designPhase 3 open label randomised controlled trial.

settingUnited Kingdom.

participants6200 people aged ≥16 years who were not taking vitamin D supplements at baseline.

interventionsOffer of a postal finger prick test of blood 25(OH)D concentration with provision of a six month supply of lower dose vitamin D (800 IU/day, n=1550) or higher dose vitamin D (3200 IU/day, n=1550) to those with blood 25(OH)D concentration <75 nmol/L, compared with no offer of testing or supplementation (n=3100). Follow-up was for six months.

main outcome measuresThe primary outcome was the proportion of participants with at least one swab test or doctor confirmed acute respiratory tract infection of any cause. A secondary outcome was the proportion of participants with swab test confirmed covid-19. Logistic regression was used to calculate odds ratios and associated 95% confidence intervals. The primary analysis was conducted by intention to treat.

resultsOf 3100 participants offered a vitamin D test, 2958 (95.4%) accepted and 2674 (86.3%) had 25(OH)D concentrations <75 nmol/L and received vitamin D supplements (n=1328 lower dose, n=1346 higher dose). Compared with 136/2949 (4.6%) participants in the no offer group, at least one acute respiratory tract infection of any cause occurred in 87/1515 (5.7%) in the lower dose group (odds ratio 1.26, 95% confidence interval 0.96 to 1.66) and 76/1515 (5.0%) in the higher dose group (1.09, 0.82 to 1.46). Compared with 78/2949 (2.6%) participants in the no offer group, 55/1515 (3.6%) developed covid-19 in the lower dose group (1.39, 0.98 to 1.97) and 45/1515 (3.0%) in the higher dose group (1.13, 0.78 to 1.63).

conclusionsAmong people aged 16 years and older with a high baseline prevalence of suboptimal vitamin D status, implementation of a population level test-and-treat approach to vitamin D supplementation was not associated with a reduction in risk of all cause acute respiratory tract infection or covid-19.

trial registrationClinicalTrials.gov NCT04579640.

Indexed as

COVID-19Respiratory Tract InfectionsVitamin D DeficiencyCholecalciferolDietary SupplementsDouble-Blind MethodHumansVitamin DVitaminsCholecalciferolVitamin DVitamins

Identifiers

PMID36215226
PMCPMC9449358
OpenAlexW4295862512

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.